Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotequeROCO:4107 +0.45%86 EV-to-EBIT is 8.42 as of Sep. 20, 2026, which is 32% below its 10-year median of 12.43. GuruFocus rates ROCO:4107 with a GF Score™ of 86/100 and a GF Value™ of NT$131.38 (Modestly Undervalued). Among 482 Medical Devices & Instruments companies, Bioteque ranks better than 79.25% on this metric.
The historical rank and industry rank for Bioteque's EV-to-EBIT or its related term are showing as below:
ROCO:4107'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7.97 Med: 12.43 Max: 24.11
Current: 8.42
During the past 13 years, the highest EV-to-EBIT of Bioteque was 24.11. The lowest was 7.97. And the median was 12.43.
ROCO:4107's EV-to-EBIT is ranked better than 79.25% of 482
companies
in the Medical Devices & Instruments industry
Industry Median: 17.95
vs ROCO:4107: 8.42
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bioteque's Enterprise Value for the quarter that ended in Jun. 2026 was NT$6,620 Mil.
Bioteque's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$759 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioteque EV-to-EBIT Related Terms
Bioteque EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bioteque's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4107 vs ISRG, BDX, RMD: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Bioteque's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioteque EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioteque's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bioteque's EV-to-EBIT falls into.
Bioteque's current Enterprise Value is NT$6,390 Mil.
Bioteque's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$759 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioteque (ROCO:4107) has a EV-to-EBIT of 8.42 as of Sep. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioteque and its competitors. This is 32% below median its historical median of 12.43. Over the past decade, Bioteque's EV-to-EBIT has ranged from 7.97 to 24.11. According to the industry distribution chart, Bioteque ranks #100 out of 482 companies in the Medical Devices & Instruments industry, placing it in the top 20.7%.
Is Bioteque's EV-to-EBIT too high?
Bioteque's current EV-to-EBIT of 8.42 is 32% below median its 10-year median of 12.43. Over the past 10 years, this metric has ranged from a low of 7.97 to a high of 24.11. The Medical Devices & Instruments industry median EV-to-EBIT is 17.95. Bioteque's value of 8.42 is 53.1% below this industry median. Based on the distribution chart, Bioteque ranks #100 out of 482 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bioteque has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bioteque ranks #100 out of 482 companies for EV-to-EBIT. This places Bioteque in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 17.95. Bioteque's value of 8.42 is 53.1% below this benchmark. Historically, Bioteque's own EV-to-EBIT has ranged from 7.97 to 24.11 over the past decade. While the company's 10-year median is 12.43 vs. the industry median of 17.95, Bioteque has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 17.95, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioteque's current EV-to-EBIT of 8.42 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioteque and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 17.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioteque's current EV-to-EBIT is 8.42, which is 32% below median its own 10-year median of 12.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$131.38, compared to a current price of NT$112.00 — trading 14.8% below its estimated fair value. The current EV-to-EBIT is 8.42, which is 32% below median its 10-year median of 12.43 and 53.1% below the Medical Devices & Instruments industry median of 17.95. Bioteque's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current EV-to-EBIT is 8.42 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioteque (ROCO:4107) Overvalued in 2026?
Based on GuruFocus' analysis, Bioteque stock appears to be undervalued.
The current stock price of NT$112.00 is trading 14.8% below its estimated GF Value™ of NT$131.38.
GuruFocus considers Bioteque to be Modestly Undervalued.
Key valuation signals for ROCO:4107:
EV-to-EBIT: 8.42 (32% below median its 10-year median of 12.43)
GF Value™: NT$131.38 vs. price of NT$112.00 (14.8% below fair value)
Industry Position: 53.1% below the Medical Devices & Instruments median (#100 of 482)
No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
86GF Score
Get the complete analysis for ROCO:4107
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4107 has been successfully added to your 
